Steroid-eluting epicardial pacing leads in pediatric patients: Encouraging early results  by Johns, James A. et al.
Permanent pacing in children presents special problems fat 
the pediatric cardiologist and the cardiac surgeon (f-17). 
These include the need to provide pacing for a period that 
may span many decades, small patient size and the common 
presence of structural congenital heart dis 
patients who require permanent pacing. 
infants and children has been performed because of brady- 
cardia produced by sinus node dysfunction or atrioventric- 
ular (AV) block. As the role of pacing for treatment (18-20) 
or prevention (21) of tachycardia expands in this patient 
group, the number of pediatric patients undergoing implan- 
tation of a permanent pacing system will continue to grow. 
Over the last decade, transvenous endocardial pacing 
leads have gained favor for use in smaller and smaller 
children including infants and children weighing ~10 kg 
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(22~27). The pacing and sensing characteristics of thcsc 
leads have generally been excellen:. Although t 
results are quit2 favorable, there is a poten 
obstruction by relatively large transve us leads (281, par- 
ticularly in children who are likely to r ire multiple pacing 
ieads over their lifetime. This problem can be of particular 
concern because of the risk of caval obstruction after atria: 
repair of transposition of the great arteries even without 
pacing leads (29-32). Transvenous access to the atrium or 
ventricle may also be limited by congenital anomalies of the 
systemic veins or by prior operations such as superior vena 
cava to pt.u rtoaary artery anastomosis (Glenn shunt), 
Fontan operation or tricuspid valve replacement (33). 
fortunately, children with complex anatomy represent a 
significant proportion of pediatric patients requiring pacing. 
Epicardial pacing has been used in a large number of 
children because of small patient size, anatomic consider- 
ations or the need to perform surgical correction of struc- 
tural congenital heart disease at the time o 
implantation. However, epicardial pacing 
ated with a high incidence of pacing or sensing problems 
requiring lead repiacement (16,34-40). Pf a reliable epicar- 
dial pacing lead were available, it might prove to be a good 
choice as a first pacing system in infants and small children, 
as well as in older children undergoing concomitant cardiac 
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Table 1. Clinical Features of Patients Undergoing Placement of Steroid-Eluting Epicardial Pacing 
Pt Age (yr)l Rhythm Concurrent Implantation 
No. Gender Cardiac Diagnosis Diagnosis Prior Operahon Operation Technique Chamber F/I_! (wan,! --I__ 
1 6/M 
2 k/F 
3 IS/F 
4 WM 
5 18/M 
6 d/F 
7 51M 
8 ‘IF 
9 2/M 
IO 3 wk/M 
II 13/M 
d-TGA 
Muscular VSD 
Common atrium, 
unroofed CS 
Mitral atresia 
AVSD 
AVSD 
DILV 
d-TGA 
DlLV 
d-TGA, VSD 
DILV. subaorlic 
stenosis 
12 2/F None 
SND 
CAVB 
SAW 
CAVB 
SAVB 
SAVB 
CAVB 
SND 
CAVB 
SAVB 
SAW3 
CAVB 
PA banding 
ASD repair. mitral 
valve replacement 
None 
Repair of AVSD 
Repair of AVSD 
PA banding 
Senning 
Coorct repair 
Arterial switch. VSD 
repair 
PA bnnding, atria1 
septcccomy. BVF 
enlargemenl. 
central shunt, 
Glenn shunt 
None 
None 
VSD repair 
None 
Atrial septectomy. 
PA band 
Mitral valvuloplasty 
None 
Glenn shunt 
None 
None 
None 
L thoracukomy 
Sternoromy 
Subxiphoid 
R thoracotomy. 
subxiphoid 
Sternotomy 
L thoracotomy 
R thoracotomy, 
subxiphoid 
L thoracotomy 
Sternotomy 
L thoracotomy 
L thoracoromy, 
repeat L 
thoracotomy 
L thoracotomy 
LV, RV 
RV (2 leads) 
RV 
RA, RV 
RA. RV 
LA 
RA, LV 
LA. LV 
WA. LV 
LA, LV 
LV, replaced with 
2 additiomll LV 
leeds 
LA. LV 
3.5 
0 
84 
82 
73 
77 
49 
74 
38 
IO 
6 
4’ 
42 
ASD = atrial septal defect: AVSD = atrioventricular septal defect; BVF = bulboventriculllr foramen: CAVB = congenital atrioventricuh block; Caarc! = 
coarctation of aorta; CS = coronary sinus: DILV = double-inlet left ventricle; d-TGA = dextrolransposition of the great arteries; F = female: F/U = follow-up 
interval; L = left: LA = left atrium; LV = left ventricle; M = male: PA = pulmonary artery: Pt = patient: R = right: RA = right atrium: RV = right ventricle: 
SAVB = surgical atrioventricular block: SND = sinus node dysfunction; VSD = ventricular septal defect. 
surgery or having anatomic abnormalities precluding trans- 
venous pacing. 
The addition of a small amount of steroid to endocardial 
pacing electrodes has appeared toimprove the pacing and 
sensing characteristics of these lectrodes (41-48). Encour- 
aged by the results obtained with endocardial steroid-eluting 
pacing electrodes and by animal studies of epicardial pacing 
electrodes (493). we undertook this study of a new porous- 
tipped steroid-eluting epicardial pacing electrode ina group 
of infants and chi!dren requiring epicardial pacing. Our 
purpose was to evaluate the pacing and sensing characteris- 
tics of this new lead in fants and children. 
Study patients. We studied I2 pediatric patients requiring 
cardiac pacemaker l ad placement over a l-year period from 
February 1990 to February 1991. Patient characteristics are 
summarized in Table 1. The patients ranged in age from 3 
weeks to 18 years (mean 2 SD 6.4 + 5.9 years) at the time 
of pacemaker implantation. Eleven patients had underlying 
structural congenital heart disease (single ventricle in four, 
d-transposition f the great arteries in three, AV septal 
defect in two, ventricular septal defect in one and common 
atrium with unroofed coronary sinus in one). Ten patients 
had undergone previous cardiac operation, inclading Sen- 
ning repair in two, AV septal defect repair in two, pulmonary 
artery banding  two, repair of common atrium with mitral 
valve replacement i  one, repair of coarctation ofthe aorta 
in one and arterial switch procedure with ventricular septal 
defect repair in one. Two patients bad sinus node dysfunc- 
tion, five had surgical complete AV block and five had high 
grade congenital AV block. Four patients had had other 
pacing leads placed before the study: two of these patients 
had steroid leads placed because of malfunction of the 
existing lead nd two had placement ofadditiona! ieads to 
allow dual-chamber pacing. 
Informed written consent was obtained from the parents 
of all patients and from those patients old enough to consent. 
The protocol was approved by the Vanderbilt University 
CommIttee for the Protection of Human Subjects on Febru- 
ary 7, 1990. This study was part of a multncenter nal of the 
lead as an investigational device performed under the control 
of the Food and Drug Administration. 
Characteristics of the lead (Fig. 1). The lead consisted of 
a porous-tipped lectrode platinized with platinum black and 
coated with dexamethasone sodium phosphate (49,50). The 
electrode contained app,qximately 1 mg of dexamethasone 
sodium phosphate in a silicone rubber binder designed to 
allow elution of the dexamethasone i to the area surround- 
ing the electrode when exposed to body fluids. The electrode 
was attached to a triangular silicone suture pad with two 
holes and proximal nd distal grooves to allow attachment to 
the epicardial surface of the heart. The conductor was a 
74ilar MP35N nickel alloy conductor with silicone insulation 
and a standard S-mm unipolar connector. All leads were 
used in a unipolar configuration. 
Surgical technique (Table I). Leads were placed by tho- 
racotomy (14 leads, eight patients), sternotomy (6 leads, 
three patients) or the subxiphoid approach (3 leads, three 
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pat~e~t§); intwo pat~ents~ atriz 
cotomy and ventricular leads 
because ofthe need fo
cardiac anatomy, previous 
iac operations at the time of 
in one, repair of ventri 
k-Han1011 atrial septet 
banding in one). Eight atria1 leads (4 right and 4 left) and 15 
ve~t~c~lar leads (6 right and 9 left) 
ln all cases, the lead was he! 
ventricular epicar ium and pacing a ensirlq characteris- 
tics of the lead were deiermined. hen a satisfactory 
position was found (generally the fi r second position 
tested), the lead was sewn i
and the proximal suture groo . After the lead had stabilized 
for 5 to 10 min, mecsurcmcn:s G% pulse width threshold at 
0.8, 1.6, 2.5 and 5 V were obtained, as well as current and 
voltage thresholds at0.05, 0.2-, 0.5 and I-ms pulse width. 
Lead impedance was measured atan amplitude of2.5 V and 
a pulse width of 0.5 ms. P or R wave amplitudes and slew 
rates were also measured. All intraoperative m asurements 
were obtained with a Medtronic model 531 I Pacing System 
measurements. Patients underwent follow-up 
pacemaker l ad analysis every week for 6 weeks, at 3 and 6 
months, and then every 6 months. At each visit, pulse width 
threshold was determined at approximately 0.8, 1.6,2,5 and 
5 V. (The actual voltages tested varied slightly depending on 
the pacemaker generator manufacturer, so that for some 
patients the voltages tested were 1, I.5,2.5 and 5.4 V.) The 
threshold was determined by decreasing the pulse width 
until there was failure to capture. The threshold was consid- 
ered to be the lowest programmable pulse width at which 
there was consistent capture. Mean pulse width threshold at 
rences between atria 
ata are xpressed as 
acement of two ventricular 
scular ve~trico~ar sepal de 
flow cardiac output unrel 
pacing leads. In two oth patiems, one lead was 
future use. Follow-up la were obtained on 
retlraining 13 leads for ean of 53 I 25 weeks (range 6to 
transposition f the great 
tricular septal defect, who died 14 weeks 
after lead placement of graft-versus host disease acquired 
from traasfusion at the time of arterial switch repair. 
through the 1st 38 weeks are included for Patient 9, who 
congestive heart failure 42 weeks after lead 
ient 1 I, who had exit block requiring replace- 
tricular lead 6 weeks after its place 
discussed in more detail later. No patient was lost to 
sed any scheduled lead an lysis. 
calds. Mean pulse width ;hresholds at im- 
plantation and throughout the follow-up eriod are show 
Table 2 and Figure 2. At imp~a~tatioo, the 
at a pulse width of 0.5 ms was 0.9 9 
rence between the atrial and 
.O.91 2 0.27 V). The pulse width threshold at 
an amplitude of 2.5 V was 0.15 & 0.08 ms and was nearly 
identical for tbe atrial and ventricular leads. On follow- 
visits, only pulse width threshold was obtained. Over 
duration of follow-up, there was no significant change in the 
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Table 2, Pulse Width Thresholds, Sensing Thresholds and Impedance on All Leads, Atria1 Leads Only and VentriCUiar k ds Only 
0.8 to 1.0 v 1.5 to I.6 v 2.5 v 5.0 to 5.4 v Sensing impedance 
--- 
Wk n* ms nt 31s rlt ms nt ms nt mV nS R nS 
A. All Leads 
0 19 0.60 c 0.29 17 0.28 r 0.20 I9 0.15 + 0.08 I9 0.08 + 0.03 19 4.80 + 1.75 17 410~72 19 
I 19 0.53 t 0.27 18 0.27 C 0.12 I8 0.15 + 0.08 I9 0.08 i 0.03 I9 4.66 t 1.79 I6 314 rt 55 I9 
2 I9 0.46 f 0.22 15 0.27 t 0.16 18 0.16 + 0.07 I9 0.07 r 0.03 I9 4.69 2 1.75 I6 305 + 45 19 
3 19 0.45 t 0.26 16 0.27 ? 0.15 I8 0.15 + 0.09 I9 0.07 f 0.03 I9 4.56 ? 1.74 I6 313 243 I9 
4 19 0.39 2 0.16 I5 0.31 f 0.29 IS 0.17 It 0.12 I9 0.07 + 0.04 I9 4.63 + 1.68 16 317243 19 
5 I9 0.37 r 0.14 I5 0.30 + 0.30 I8 0.15 + 0.11 I8 0.10 f 0.17 I9 4.61 ?r 1.73 16 323 + 36 I9 
6 I8 0.38 + 0.18 I4 0.29 e 0.25 I7 0.14 2 0.10 I7 0.07 * 0.04 I7 4.72 2 1.69 I6 319+51 18 
I2 I7 0.38 + 0.16 15 0.26 4 0.18 I7 0.14 it 0.08 I7 0.06 + 0.04 I7 4.69 + 1.73 I6 334 r 47 I8 
24 I6 0,52 I 0.35 IS 0.24 + 0.13 I5 0.15 c 0.08 I6 0.M + 0.04 I6 4.71 rt 1.70 14 357 2 43 16 
52 II OS44 IO.21 II 0.22 + 0.07 II 0.13 + 0.03 II 0.06 + 0.03 II 4.82 ” 1.64 II 368~49 II 
78 9 0.45 + 0.22 9 0.21 + 0.07 9 0.13 + 0.03 9 0.07 c 0.03 9 4.89 + 1.66 9 378 + 61 9 
B. Atrial Leads Only 
~_____l____ “l..--. ,-~ ~~_-._- 
0 tl 0.71 + 0.36 7 0.29 + 0.14 8 0.16 ?: 0.08 8 0.08 ” 0.03 8 3.25 k 0.50 8 374 c 44 8 
I 8 0.43 * 0.19 8 0.24 C 0.10 8 0.11 to.03 8 0.06 % 0.02 8 3.06 i: 0.63 8 328 ” 65 8 
2 8 0.34 9 0.15 8 0.18 ” 0.06 tl 0.12 ?: 0.02 8 0.05 r 0.02 8 3.13 -‘- 0.5s 8 314rt52 8 
3 8 0.31 2 0.12 N 0.18 -c 0.07 8 0.11 ” 0.03 8 0.05 ? 0.02 lt 3.00 1 0.56 8 307 c 38 8 
4 8 0.32 + 0.16 8 0.18 + 0.07 8 0.11 + 0.02 8 0.05 i: 0.03 8 3.13 c 0.55 8 319244 8 
5 8 0.31 t 0.13 8 0.16 + 0.05 8 0.10 + 0.03 8 0.04 + 0.01 8 3.10 + 0.76 8 325 r 33 8 
6 7 0.28 + 0.09 7 0.16 + 0.03 7 0.09 * 0.02 7 0.04 2 0.01 7 3.19 c 0.56 8 324 z!z 52 8 
12 7 0.25 ” 0.08 7 0.15 + 0.05 7 0.10 lr 0.03 7 0.03 + 0.01 7 3.14 I?: 0.67 8 337 + 50 8 
24 7 0.29 T. 0.10 7 0.16 + 0.04 7 0.10 f 0.03 7 0.04 2 0.01 7 3 I4 -c 0.58 7 354 + 45 7 
52 5 0.29 2 0.07 5 0.17 f 0.04 5 0.10 + 0.00 5 3.04 t 0.01 5 3.2@ + 0.40 5 356 r 29 5 
78 4 0.26 + 0.08 4 0.16 2 0.05 4 0.11 f 0.02 4 0.04 + 0.01 4 3.25 T 0.43 4 362 t 44 4 
C. Ventricular Leads Only 
0 II 0.52 + 0.20 IO 0.28 ? 0.24 II 0.15 + 0.08 II 0.07 * 0.03 I I 6.17 ” I.25 9 436 + 77 I I 
I II 0.61 i 0.23 I(! 0.31 r 0.12 IO 0.18 t 0.08 II 0.10 + 0.03 II 6.25 2 0.97 8 304243 II 
2 II 0.58 2 0.21 7 0.36 2 0.16 IO 0.19 i 0.08 I I 0.09 + 0.03 II 6.25 + 0.97 a 298 ? 39 I I 
3 II 0.58 * 0.29 8 0.35 + 0.15 IO 0.19 + 0.11 II 0.09 + 0.03 I I 6.13 z! 0.93 8 316245 II 
4 II 0.4! + 0.11 7 0.42 - 0.34 IO 0.22 2 0.14 II 0.08 -c 0.04 II 6.13 c 0.93 8 316’41 II 
s II 0.44 f 0.13 7 0.41 + 0.36 IO 0.19 * 0.14 IO 0.15 ir 0.21 II 6.13 + 0.93 8 322238 II 
6 II 0.48 + 0.19 7 0.39 c 0.30 IO 0.18 + 0.11 IO 0.08 + 0.04 IO 6.25 + 0.83 8 315*51 IO 
i2 IO 0.50 t 0.12 8 0.35 + 0.19 IO 0.18 ? 0.08 IO 0.08 + 0.03 10 6.25 2 0.83 8 332 2 46 IO 
24 9 0.73 f 0.35 8 0.33 t 0.14 a 0.19 + 0.09 9 0.08 + 0.04 9 6.29 k 0.70 7 350 t 42 9 
52 6 0.56 t 0.21 6 0.27 t 0.07 6 0.15 2 0.03 6 0.07 f 0.03 6 6.17 k 0.90 6 377 + 42 6 
78 5 0.60 I 0.18 5 0.25 * 0.07 5 0.15 + 0.03 5 0.09 ? 0.02 5 6.20 If: 0.98 5 390 t 69 5 
*Number of leads for which pulse width threshold was measured. th’umber of leads capturrng nt indicated voltage. $Number of leads for which sensing was 
measured. DNumber of leads for which impedance was measured. 
mean pulse width threshold for all leads, although t ere were 
significant d&ereaces in threshold between the atrial and 
ventricular leads. 
For the atrial leads, there was a significant decrease in
pulse width threshold with time (Table 28, Fig. iB) (by 
analysis of variance p < 0.0005 at an amplitude of I V, p < 
0.05 at 1.5 V, p = 0.08 at 2.5 V and p < 0.005 at 5.4 V). The 
decline was most apparent within the 1st week after implan- 
tation, with little change thereafter. No atrial lead dem- 
onstrated any significant increase in threshold. and ail 
follow-up ulse width thresholds were lower than the thresh- 
olds at implantation. 
In contrast o the atrial leads, the ventricular leads 
showed no significant difference in pulse width threshold 
with time. Mean pulse width threshold for the ventricular 
leads is shown in Table 2C and Figure 2C. Ten of the II 
ventricular leads howed an increase in pulse width thresh- 
old to a level greater than that at implantation. The time of 
the maximal threshold for these ventricular leads ranged 
from I to 32 weeks (median 3, mean I2 weeks). Despite these 
increases, the mean pulse width threshold for the ventricular 
leads at 2.5 V was still only 0.19 + 0.09 ms at 6 months 
and 0.15 + 0.03 ms at I2 months. By analysis of variance, 
pulse width threshold for the atrial eads was significantly 
lower than for the ventricular leads at all amplitudes 
(p < O.OOOOP at 0.8 to I V, I.5 to 1.6 V and 2.5 V; p < 0.00005 
at 5 to 5.4 V). 
Patient I I deserves special mention because of a marked 
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Follow-up Duration (weeks) 
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6 Volts 
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Follow-up Duration (weak) 
Ventricular Leads 
1 
5 
; 0.9 
g. O.&l 
; 0.7 
f 0.G 
o! c 0.5 
; 0.4 
fG 
z 
0.3 
% 0.2 
z 0.1 
0 
0 1 2 3 4 5 6 12245276 
Follow-up Duratlon (weeks) 
Figare 2. Pulse width threshold for all leads (A), atrial leads ( 
ventricular leads (C), shown as a function of time after implantation. 
Numbers indicate the number of ltads at each follow-up interval. 
Strength-duration curves are shown on the Y and Z axes at each 
follow-up intervai. There was no significant change inthreshold over 
time for all leads (A) or ventricular leads (B), but the threshold for
atrial eads (B) decreased significantly. 
itxrezse ia threshold Oiier time. This iSyear old boy with a 
double-inlet left ventricle had developed complete AV block 
at the time of surgical enlargement of the bulboventricular 
foramen. He underwent placement oftransvenous atrial and 
ventricular endocardial pacing leads and subsequent anasto- 
mosis of the right pulmonary artery to the superior vena cava 
superior vena cava arose% 
tra~svc~o~s access t
6 weeks, there was 
de at th:: maximal 
s HI0 possibility of 
nd to skew the mean thre 
iately at the mini 
for atrial eads and 
illplantation or during follow-up. 
s. These data indi- 
cate that over a period of to h year, pacing and sens 
characteristics of this new steroid-eluting pacing lead 
mained excellent. ~~fortu~ate~y, there are few similar pro- 
spective studies to allow compariso this lead with other 
epicardial leads. Hengiein et al. (39) 
pulse width threshold ia several dl t e~doca~dial and 
epicardial e ectrodes, and found that here was a substantial 
increase in pulse width threshold of the epicardial ventricu- 
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lar leads, peakilrg at approximately 0.33 ms at 5 V, between 
5 weeks and 6 months after pacemaker implantation. The 
steroid-eluting ventricular leads we tested showed a similar 
increase, although the peak threshold of our leads Was 
considerably lower. Kugler et al. (38), in a retrospective 
study of two different epicardial leads, reported long-term 
ventricular pulse width thresholds similar to !hose we ob- 
served. However, it is difficult to compare our data with 
theirs because their “chronic” thresholds were obtained at 
various times at least 6 weeks after pacemaker implantation. 
At 6 months, our mean atrial lead pulse width threshold at 
2.5 V (0.1 + 0.03 ms) was lower than that reported by Ott 
(50) (0.18 ?Z 0.18 ms), and the difference may be even 
greater, because some or all of Ott’s thresholds may have 
been at a 5-V amplitude. 
ifferences between atrial and ventricular leads. The dif- 
ference in the pulse width threshold between our atrial and 
ventricular lcads was intcrcsting. Unlike the ventricular 
leads, virtually all OF which demonstrated an increase in 
pulse width threshold at least transiently, the atrial leads 
showed a decrease in pulse width threshold with time. 
Kugler et al. @I), using a similar epicardial electrode in 
swine, demonstrated a lower atrial pacing threshold with a 
steroid-eluting version than with a nonsteroid-eluting ver- 
sion, but ventricular pacing threshold did not differ between 
electrodes. 
Mechanism of steroid effect. The mechanism by which 
dexamethasone improves pacing and sensing thresholds is 
not fully understand: presumably, the drug decreases the 
fibrous tissue formation or the inflammation around the 
electrode, allowing more effective stimulation of the myo- 
cardium (48). Direct electrophysiologic effects of dexam- 
ethasone may explain some. but not all, of the difference 
between steroid and nonsteroid-eluting electrodes (52). The 
platinized porous tip may also play a role in decreasing 
fibrous tissue formation (53). Karpawich et al, (54) recently 
compared steroid-eluting and nonsteroid-eluting versions of 
an epicardial pacing lead and found that initial thresholds 
were similar, but that the thresholds of the nonsteroid- 
cluting leads increased with time whereas those of the 
steroid-eluting leads did not. 
Clinical implications. The availability of a reliable atrial 
epicardial pacing lead will be an important advance for 
children who are not good candidates for transvenous atriaI 
leads. In some of these patien!s there is limited or no venous 
access to the atrium from the superior vena cava, either 
because of caval obstruction after atrial repair of transposi- 
tion of the great arteries or because of a Glenn shunt. In 
children with AV block who will require pacing for the 
remainder of their lives, epicardial atrial leads may allow AV 
synchrony at an earlier age without the risk of caval obstruc- 
tion. Karpawich et al. (55) found that fixed rate ventricular 
Pacing in puppies predisposes to myoceliular disruption. 
Some of these changes may be related to the fixed rate 
pacing rather than to lack of AV synchrony. Rate-responsive 
(WW pacing may be an alternative with more favorable 
hemodynamic effects than those of fixed rate pacing (56-58), 
but it does not provide AV synchrony. Only with an atri 
lead that can reliably sense the atrial activity are both A 
synchrony and rate respcnsiveness possible (2038). In ad- 
dition, antitachycardia pacing, which is being recognized as 
an attractive alternative to pharmacologic therapy of su 
praventricular tachycardias (l8-20), requires reliable atrial 
sensing and pacing. Finally, lower pacing thresholds with 
steroid-eluting epicardial pacing leads will allow lower gen- 
erator outputs with maintenance of an adequate safety 
margin. Pacing can now be performed in all af our patients 
using an amplitude of 1.5 to 2.5 V at a 
0.5 ms while maintaining a >2:l safety 
conclusions. Over a period of up t 
steroid-eluting epicardial pacing leads have retained excel- 
lent pacing and sensing characteristics. If these ing 
early results continue, epicardial steroid-eluting be 
an attractive option for infants and children requiring pacing. 
Clearly, transvenous endocardial pacing is tke preferred 
route for pacing in most older children, but there will 
continue to be a group of patients who require epicardial 
pacing because of small patient size, inadequate transvenous 
access to the atrium or ventricle or the need for concomitant 
cardiac surgery at the time of pacemaker implantation. The 
availability of epicarJd leads with reliable pacing and 
sensing of both the atrium and the ventricle may also allow 
smaller infants to undergo dual-chamber pacing, giving them 
the benefits of AV synchrony. 
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